Detalles de la búsqueda
1.
Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
Int J Mol Sci
; 22(18)2021 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34576020
2.
Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression.
J Carcinog
; 18: 3, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31360124
3.
Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.
Carcinogenesis
; 32(12): 1773-81, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21940908
4.
Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy.
Cancers (Basel)
; 12(5)2020 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32455829
5.
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma.
Life (Basel)
; 10(11)2020 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33238591
6.
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
Cells
; 8(6)2019 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31159302
7.
Novel aminochromone derivative inhibits tumor growth on xenograft model of lung cancer in mice.
J Adv Pharm Technol Res
; 9(4): 130-134, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30637230
Resultados
1 -
7
de 7
1
Próxima >
>>